News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
41,486 Results
Type
Article (2712)
Company Profile (45)
Press Release (38728)
Multimedia
Podcasts (10)
Webinars (3)
Section
Business (14448)
Career Advice (89)
Deals (2151)
Drug Delivery (10)
Drug Development (4293)
Employer Resources (12)
FDA (474)
Job Trends (827)
News (20937)
Policy (1473)
Tag
Academia (157)
Allergies (10)
Alliances (3542)
ALS (6)
Alzheimer's disease (97)
Antibody-drug conjugate (ADC) (27)
Approvals (482)
Artificial intelligence (32)
Autoimmune disease (8)
Automation (2)
Bankruptcy (12)
Best Places to Work (517)
BIOSECURE Act (2)
Biosimilars (16)
Biotechnology (29)
Bladder cancer (8)
Brain cancer (7)
Breast cancer (45)
Cancer (328)
Cardiovascular disease (11)
Career advice (77)
Career pathing (1)
CAR-T (31)
CDC (2)
Cell therapy (83)
Cervical cancer (2)
Clinical research (3530)
Collaboration (202)
Company closure (2)
Compensation (104)
COVID-19 (219)
CRISPR (11)
C-suite (117)
Cystic fibrosis (8)
Data (432)
Denatured (6)
Depression (12)
Diabetes (18)
Diagnostics (504)
Digital health (2)
Diversity (2)
Diversity, equity & inclusion (1)
Drug discovery (37)
Drug pricing (11)
Duchenne muscular dystrophy (41)
Earnings (4598)
Editorial (5)
Employer branding (1)
Employer resources (10)
Events (6552)
Executive appointments (135)
FDA (631)
Friedreich's ataxia (4)
Frontotemporal dementia (1)
Funding (169)
Gene editing (33)
Generative AI (1)
Gene therapy (60)
GLP-1 (63)
Government (326)
Guidances (24)
Healthcare (781)
HIV (1)
Huntington's disease (5)
IgA nephropathy (12)
Immunology and inflammation (34)
Immuno-oncology (14)
Indications (4)
Infectious disease (233)
Inflammatory bowel disease (15)
Inflation Reduction Act (6)
Influenza (8)
Intellectual property (26)
Interviews (9)
IPO (1026)
IRA (7)
Job creations (297)
Job search strategy (72)
JPM (5)
Kidney cancer (6)
Labor market (12)
Layoffs (53)
Leadership (4)
Legal (247)
Liver cancer (6)
Longevity (1)
Lung cancer (28)
Lymphoma (12)
Machine learning (3)
Management (5)
Manufacturing (53)
MASH (14)
Medical device (339)
Medtech (341)
Mergers & acquisitions (1246)
Metabolic disorders (74)
Multiple sclerosis (22)
Neurodegenerative disease (36)
Neuropsychiatric disorders (12)
Neuroscience (207)
Neurotech (1)
NextGen: Class of 2026 (375)
Non-profit (176)
Now hiring (11)
Obesity (33)
Opinion (20)
Ovarian cancer (18)
Pain (24)
Pancreatic cancer (21)
Parkinson's disease (12)
Partnered (4)
Patents (55)
Patient recruitment (26)
Peanut (2)
People (5957)
Pharmaceutical (5)
Phase 1 (1493)
Phase 2 (1735)
Phase 3 (955)
Pipeline (399)
Policy (18)
Postmarket research (38)
Preclinical (641)
Press Release (2)
Prostate cancer (7)
Psychedelics (3)
Radiopharmaceuticals (14)
Rare diseases (67)
Real estate (427)
Recruiting (7)
Regulatory (1152)
Reports (7)
Research institute (157)
Resumes & cover letters (9)
Rett syndrome (1)
RNA editing (6)
RSV (2)
Schizophrenia (17)
Series A (47)
Series B (21)
Service/supplier (2)
Sickle cell disease (4)
Special edition (5)
Spinal muscular atrophy (2)
Sponsored (1)
Startups (499)
Stomach cancer (2)
Supply chain (4)
Tariffs (2)
The Weekly (4)
Vaccines (58)
Venture capital (16)
Weight loss (21)
Women's health (10)
Worklife (1)
Date
Last 7 days (40)
Last 30 days (160)
Last 365 days (2470)
2026 (218)
2025 (2499)
2024 (2661)
2023 (2944)
2022 (3837)
2021 (4252)
2020 (3657)
2019 (2211)
2018 (1651)
2017 (1833)
2016 (1678)
2015 (1881)
2014 (1418)
2013 (1216)
2012 (1450)
2011 (1380)
2010 (1209)
Location
Africa (51)
Alabama (3)
Arizona (21)
Asia (2045)
Australia (349)
California (1607)
Canada (242)
China (80)
Colorado (54)
Connecticut (16)
Delaware (7)
Europe (4186)
Florida (65)
Georgia (11)
Hawaii (2)
Idaho (3)
Illinois (25)
India (2)
Indiana (61)
Japan (27)
Kansas (14)
Kentucky (1)
Maryland (50)
Massachusetts (583)
Michigan (14)
Minnesota (22)
Mississippi (1)
Missouri (4)
Nebraska (1)
Nevada (3)
New Hampshire (4)
New Jersey (142)
New York (82)
North Carolina (133)
Northern California (786)
Ohio (44)
Oklahoma (2)
Oregon (6)
Pennsylvania (111)
Puerto Rico (1)
Rhode Island (2)
South America (48)
South Carolina (1)
Southern California (653)
Tennessee (4)
Texas (158)
United States (3258)
Utah (5)
Virginia (11)
Washington D.C. (4)
Washington State (95)
West Virginia (1)
Wisconsin (13)
41,486 Results for "vigilant biosciences".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Neurodegenerative disease
Vigil’s TREM2 Antibody for Rare Brain Disease Flunks Phase II Trial
Disappointing results for iluzanebart come shortly after Vigil Neuroscience struck a buy-out deal with Sanofi, but analysts say the outcome is unsurprising and shouldn’t affect the deal.
June 4, 2025
·
2 min read
·
Dan Samorodnitsky
Alzheimer’s disease
Vigil’s TREM2-Targeted Alzheimer’s Treatment Shows Early Promise, Moves On to Phase II
Vigil Neuroscience reported a strong safety profile and 50% sTREM2 reduction in an early-stage trial for VG-3927, potentially representing a new avenue for treating Alzheimer’s disease.
January 23, 2025
·
2 min read
·
Dan Samorodnitsky
Press Releases
Gradalis’ Vigil® Demonstrates Significant Survival Benefit in cTMB-H / HRP Ovarian Cancer Patients; Phase 2b VITAL Trial Analysis Published in JCO – Precision Oncology
January 15, 2026
·
8 min read
Press Releases
Press Release: Sanofi completes the acquisition of Vigil Neuroscience, Inc.
August 6, 2025
·
5 min read
Mergers & acquisitions
Sanofi Buys Vigil for $470M Upfront, Reigniting a Battered Alzheimer’s Target
The deal helps revitalize the TREM2 target after the high-profile failure of AbbVie and Alector’s candidate last year.
May 22, 2025
·
4 min read
·
Annalee Armstrong
Press Releases
Change in Number of Shares and Votes in Alligator Bioscience AB
February 1, 2026
·
1 min read
Press Releases
Imbed Biosciences Secures Strategic Investment from BioLab Holdings
February 4, 2026
·
2 min read
Press Releases
Invitation to Alligator Bioscience’s Earnings Call on 12 February 2026
February 5, 2026
·
1 min read
Press Releases
Genflow Biosciences PLC Announces Directorate Change
January 19, 2026
·
6 min read
Press Releases
Press Release: Sanofi to acquire Vigil Neuroscience, Inc., adding a new investigational medicine to treat Alzheimer’s disease to the neurology pipeline
May 22, 2025
·
9 min read
1 of 4,149
Next
